Neuroinflammation in Disease: Risk Factors, Management & Outcomes | Agenda Bookshop Skip to content
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Rebecca K. Dawson
Category1=Non-Fiction
Category=MJN
Category=MMF
Category=PSAN
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=In stock
Price_€100 and above
PS=Active
softlaunch

Neuroinflammation in Disease: Risk Factors, Management & Outcomes

English

In this book, the link between the modifiable risk factors of neurodegenerative diseases and chronic neuroinflammation are examined, thus highlighting that controlling risk factors is a valid approach for managing neurodegnerative diseases in which neuroinflammation contributes to the disease progression. The mechanisms of inhibition of neuroinflammation by EST and ERAs are discussed, as well as the neuroprotective roles of EST and ERAs in multiple sclerosis, Alzheimer''''s disease, Parkinson''''s disease and epilepsy. The final chapter focuses on the dynamics of progression in MS patients, and the disease process within contexts of proinflammatory reactivity and interactivity. See more
Current price €122.54
Original price €128.99
Save 5%
Age Group_Uncategorizedautomatic-updateB01=Rebecca K. DawsonCategory1=Non-FictionCategory=MJNCategory=MMFCategory=PSANCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=In stockPrice_€100 and abovePS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Weight: 174g
  • Dimensions: 155 x 230mm
  • Publication Date: 01 Sep 2015
  • Publisher: Nova Science Publishers Inc
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9781634833899
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept